How will you decide between using paclitaxel-coated balloons versus conventional uncoated balloons for managing in-stent restenosis?

Recent data (AGENT IDE trial) have suggested that target vessel failure rates are significantly lower in paclitaxel-coated balloons versus conventional balloon angioplasties when used to treat in-stent restenosis (ISR).

The drug-coated balloon for managing in-stent restenosis is a major step forward...